Chong Kun Dang Holdings Corp. (001630.KS)
KRW 50100.0
(-0.6%)
KRW 50100.0
(-0.6%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 371.49 Billion KRW | -6.94% |
| 2022 | 399.18 Billion KRW | -9.57% |
| 2021 | 441.4 Billion KRW | 6.65% |
| 2020 | 413.89 Billion KRW | 25.93% |
| 2019 | 328.66 Billion KRW | 61.96% |
| 2018 | 202.93 Billion KRW | 21.51% |
| 2017 | 167 Billion KRW | 62.88% |
| 2016 | 102.52 Billion KRW | 46.12% |
| 2015 | 70.16 Billion KRW | 20.09% |
| 2014 | 58.42 Billion KRW | -79.49% |
| 2013 | 284.85 Billion KRW | -4.94% |
| 2012 | 299.65 Billion KRW | -2.41% |
| 2011 | 307.05 Billion KRW | 4.16% |
| 2010 | 294.79 Billion KRW | 22.65% |
| 2009 | 240.35 Billion KRW | 17.01% |
| 2008 | 205.4 Billion KRW | 23.01% |
| 2007 | 166.98 Billion KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 115.43 Billion KRW | 19.92% |
| 2024 Q2 | 110.24 Billion KRW | -4.5% |
| 2023 Q3 | 95.75 Billion KRW | -0.66% |
| 2023 Q2 | 96.39 Billion KRW | 5.19% |
| 2023 Q1 | 91.63 Billion KRW | -0.16% |
| 2023 Q4 | 96.25 Billion KRW | 0.52% |
| 2023 FY | 371.49 Billion KRW | -6.94% |
| 2022 Q4 | 91.78 Billion KRW | -8.45% |
| 2022 Q1 | 108.85 Billion KRW | 8.46% |
| 2022 FY | 399.18 Billion KRW | -9.57% |
| 2022 Q2 | 98.28 Billion KRW | -9.71% |
| 2022 Q3 | 100.25 Billion KRW | 2.01% |
| 2021 Q2 | 113.8 Billion KRW | -7.4% |
| 2021 FY | 441.4 Billion KRW | 6.65% |
| 2021 Q4 | 100.36 Billion KRW | -3.81% |
| 2021 Q1 | 122.9 Billion KRW | 13.17% |
| 2021 Q3 | 104.34 Billion KRW | -8.31% |
| 2020 Q4 | 108.59 Billion KRW | 3.89% |
| 2020 Q2 | 98.89 Billion KRW | -2.93% |
| 2020 Q1 | 101.87 Billion KRW | 24.1% |
| 2020 FY | 413.89 Billion KRW | 25.93% |
| 2020 Q3 | 104.52 Billion KRW | 5.7% |
| 2019 Q4 | 82.09 Billion KRW | -1.53% |
| 2019 FY | 328.66 Billion KRW | 61.96% |
| 2019 Q1 | 70.11 Billion KRW | 25.92% |
| 2019 Q2 | 86.42 Billion KRW | 23.26% |
| 2019 Q3 | 83.37 Billion KRW | -3.54% |
| 2018 Q1 | 42.73 Billion KRW | 5.03% |
| 2018 Q2 | 46.79 Billion KRW | 9.49% |
| 2018 Q4 | 55.68 Billion KRW | 7.74% |
| 2018 Q3 | 51.68 Billion KRW | 10.46% |
| 2018 FY | 202.93 Billion KRW | 21.51% |
| 2017 Q4 | 40.68 Billion KRW | -15.27% |
| 2017 Q2 | 42.15 Billion KRW | 17.21% |
| 2017 Q1 | 35.96 Billion KRW | 17.16% |
| 2017 FY | 167 Billion KRW | 62.88% |
| 2017 Q3 | 48.02 Billion KRW | 13.92% |
| 2016 Q3 | 27.57 Billion KRW | 26.07% |
| 2016 Q1 | 22.23 Billion KRW | 8.89% |
| 2016 Q4 | 30.69 Billion KRW | 11.31% |
| 2016 FY | 102.52 Billion KRW | 46.12% |
| 2016 Q2 | 21.87 Billion KRW | -1.63% |
| 2015 Q1 | 13.64 Billion KRW | 11.21% |
| 2015 Q4 | 20.42 Billion KRW | -1.93% |
| 2015 Q3 | 20.82 Billion KRW | 37.0% |
| 2015 Q2 | 15.2 Billion KRW | 11.45% |
| 2015 FY | 70.16 Billion KRW | 20.09% |
| 2014 Q1 | 16.67 Billion KRW | -61.19% |
| 2014 Q4 | 12.26 Billion KRW | -13.9% |
| 2014 FY | 58.42 Billion KRW | -79.49% |
| 2014 Q3 | 14.24 Billion KRW | -4.71% |
| 2014 Q2 | 14.95 Billion KRW | -10.34% |
| 2013 Q2 | 85.03 Billion KRW | 11.72% |
| 2013 Q3 | 80.79 Billion KRW | -4.99% |
| 2013 Q4 | 42.97 Billion KRW | -46.81% |
| 2013 FY | 284.85 Billion KRW | -4.94% |
| 2013 Q1 | 76.11 Billion KRW | -1.82% |
| 2012 Q1 | 56.68 Billion KRW | 0.0% |
| 2012 Q2 | 76.51 Billion KRW | 34.98% |
| 2012 Q3 | 81.76 Billion KRW | 6.85% |
| 2012 Q4 | 77.53 Billion KRW | -5.18% |
| 2012 FY | 299.65 Billion KRW | -2.41% |
| 2011 Q2 | 69.39 Billion KRW | 7.8% |
| 2011 FY | 307.05 Billion KRW | 4.16% |
| 2011 Q1 | 64.37 Billion KRW | 0.0% |
| 2011 Q3 | 67.23 Billion KRW | -3.12% |
| 2011 Q4 | - KRW | -100.0% |
| 2010 Q3 | 63.52 Billion KRW | -4.88% |
| 2010 Q4 | - KRW | -100.0% |
| 2010 FY | 294.79 Billion KRW | 22.65% |
| 2010 Q2 | 66.78 Billion KRW | 11.8% |
| 2010 Q1 | 59.73 Billion KRW | 0.0% |
| 2009 Q3 | 53.93 Billion KRW | -0.32% |
| 2009 Q4 | - KRW | -100.0% |
| 2009 Q2 | 54.1 Billion KRW | 10.02% |
| 2009 Q1 | 49.17 Billion KRW | 0.0% |
| 2009 FY | 240.35 Billion KRW | 17.01% |
| 2008 Q1 | 42.35 Billion KRW | 0.0% |
| 2008 Q3 | 45.74 Billion KRW | -1.74% |
| 2008 Q4 | - KRW | -100.0% |
| 2008 Q2 | 46.55 Billion KRW | 9.91% |
| 2008 FY | 205.4 Billion KRW | 23.01% |
| 2007 Q1 | 37.44 Billion KRW | 0.0% |
| 2007 Q4 | - KRW | -100.0% |
| 2007 Q3 | 40.08 Billion KRW | -3.07% |
| 2007 Q2 | 41.34 Billion KRW | 10.42% |
| 2007 FY | 166.98 Billion KRW | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -698.832% |
| Dong-A Socio Holdings Co., Ltd. | 364.1 Billion KRW | -2.029% |
| Ildong Holdings Co., Ltd. | 198.88 Billion KRW | -86.788% |
| HANDOK Inc. | 151.36 Billion KRW | -145.429% |
| Kukje Pharma Co., Ltd. | 67.22 Billion KRW | -452.622% |
| Yuhan Corporation | 564.5 Billion KRW | 34.191% |
| Dong-A ST Co., Ltd. | 322.21 Billion KRW | -15.296% |
| SAMSUNG PHARM. Co., LTD. | 23.74 Billion KRW | -1464.393% |
| Hanmi Pharm. Co., Ltd. | 835.85 Billion KRW | 55.555% |
| Hanall Biopharma Co.,Ltd | 75.03 Billion KRW | -395.069% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | -86.718% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.64 Billion KRW | -813.902% |
| MYUNGMOON Pharm co.,Ltd | 94.51 Billion KRW | -293.055% |
| Hana Pharm Co., Ltd. | 140.85 Billion KRW | -163.743% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -698.832% |
| Ilsung Pharmaceuticals Co., Ltd. | 34.71 Billion KRW | -970.111% |
| REYON Pharmaceutical Co., Ltd. | 76.81 Billion KRW | -383.605% |
| Aprogen pharmaceuticals,Inc. | -12.04 Billion KRW | 3184.09% |
| JW Holdings Corporation | 446.15 Billion KRW | 16.734% |
| Ildong Pharmaceutical Co., Ltd. | 207.53 Billion KRW | -79.001% |
| Chong Kun Dang Pharmaceutical Corp. | 655.34 Billion KRW | 43.313% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | -10.673% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | -372.524% |
| Hyundai Pharmaceutical Co., Ltd. | 75.23 Billion KRW | -393.763% |
| Samil Pharmaceutical Co.,Ltd | 72.21 Billion KRW | -414.457% |
| Jeil Pharmaceutical Co.,Ltd | 183.81 Billion KRW | -102.105% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -698.832% |
| Kwang Dong Pharmaceutical Co., Ltd. | 295.11 Billion KRW | -25.881% |
| Daewoong pharmaceutical Co.,Ltd | 681.55 Billion KRW | 45.492% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | -10.673% |
| Yuhan Corporation | 564.5 Billion KRW | 34.191% |
| Jeil Pharma Holdings Inc | 201.82 Billion KRW | -84.072% |
| Yungjin Pharm. Co., Ltd. | 70.93 Billion KRW | -423.685% |
| Suheung Co., Ltd. | 99.02 Billion KRW | -275.147% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | -10.673% |
| Samjin Pharmaceuticals Co., Ltd. | 145.89 Billion KRW | -154.64% |
| Korea United Pharm Inc. | 173.48 Billion KRW | -114.135% |
| CKD Bio Corp. | 5.01 Billion KRW | -7314.673% |
| Daewon Pharmaceutical Co., Ltd. | 254.23 Billion KRW | -46.125% |
| Dongwha Pharm.Co.,Ltd | 184.12 Billion KRW | -101.764% |
| Whan In Pharm Co.,Ltd. | 98.12 Billion KRW | -278.595% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | -372.524% |
| Boryung Corporation | 333.26 Billion KRW | -11.471% |
| Bukwang Pharmaceutical Co., Ltd. | 50.04 Billion KRW | -642.319% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | -86.718% |
| JW Lifescience Corporation | 51.32 Billion KRW | -623.814% |